Bond.az White LogoBond.az Black Logo

Tupy S.A. Q1 2026 loss, revenue beats expectations

Tupy S.A. Q1 2026 results: EPS misses expectations, but revenue beats. Stock declines, but Bond.az analysis shows value potential.

John Smith
ByJohn Smith- Senior Editor
|
0

Tupy S.A. reported a significant earnings miss for Q1 2026. EPS came in at -0.4712, well below the forecasted -0.1094, a surprise of -330.71%.

However, revenue exceeded expectations. The company posted 2.33 billion BRL against the anticipated 2.21 billion BRL, a positive surprise of 5.43%.

Tupy's stock fell 2.63% to close at 13.67 BRL following the announcement. The stock remains near its 52-week low.

Bond.az analysis suggests the stock appears undervalued. Fair Value indicates potential upside of 47%.

Outlook: Negative EPS expected in coming quarters, but improvement projected for fiscal years 2026 and 2027.

More News
Today / 15:51
|
858

Grupo Mateus Q1 2026: EPS Misses Estimates, Stock Steady

Grupo Mateus Q1 2026 EPS missed by 30.53%, revenue slightly below. Shares stable up 0.47%.

0
Today / 15:33
|
912

TOMI Q1 2026: Revenue growth and 13% stock surge

TOMI Environmental Solutions Q1 2026 revenue rose 5% to $1.65M, stock surged 13%. EPS missed but investor confidence remained high.

0
Today / 15:31
|
482

ARS Pharma Misses Q1 2026 EPS Forecast, Stock Drops

ARS Pharma Q1 2026 EPS miss leads to 8.56% stock drop. Neffy prescriptions triple but high costs pressure profits.

0
Today / 15:31
|
228

American Strategic Co. Revenue Drops in Q1 2026

American Strategic Investment Co. revenue drops 40.7% in Q1 2026. Stock at $9.90. Bond.az analysis suggests undervaluation.

0
Today / 14:40
|
577

Sumitomo Pharma Q4 2025 Beats EPS Forecasts

Sumitomo Pharma Q4 2025 earnings beat EPS forecasts. The company achieved record profitability in FY 2025, driven by strong U.S. sales of ORGOVYX and GEMTESA.

0
Today / 13:51
|
928

MiNK Therapeutics Q1 2026: Strategic Progress

MiNK Therapeutics Q1 2026 earnings: strategic progress, financial results, and updates on AGENT-797 platform.

0
Today / 13:24
|
927

Kepler Weber Q1 2026: Mixed Results

Kepler Weber reported mixed Q1 2026 results with international growth offsetting domestic declines. EBITDA margin stable at 11%.

0
Today / 13:22
|
695

Acumen Pharmaceuticals Beats Q1 2026 EPS Forecast

Acumen Pharmaceuticals beats Q1 2026 EPS forecast with -$0.33, but stock falls on cautious sentiment. Details on ALTITUDE-ad trial and EBD program.

0
Today / 13:21
|
214

Alico Beats Q2 2026 EPS Forecast by 23%

Alico (ALCO) reports Q2 fiscal 2026 EPS of $1.49, beating estimates by 23%. The company pivots from citrus to land monetization, boosting profitability.

0
Today / 13:20
|
536

PAVmed Q1 2026: Restructuring Gains Highlighted

PAVmed Inc. reported Q1 2026 results with restructuring gains and product development progress. Stock up 3.1%.

0
Today / 13:13
|
922

Lifeward strategic moves amid revenue decline

Lifeward reports Q1 2026 revenue decline but gains investor confidence through strategic acquisitions. Read more on Bond.az.

0
Today / 13:10
|
238

Friedrich Vorwerk Q1 2026: Strong Results, Stock Drops

Friedrich Vorwerk Q1 2026 results: strong financials, stock drop. Growth expected in hydrogen and energy transition.

0
...
Tupy S.A. Q1 2026 loss, revenue beats expectations | Bond.az